Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for individuals afflicted with severe or life-threatening illnesses. A key focus is bardoxolone methyl (often referred to as bardoxolone), which is currently undergoing Phase 3 clinical trials for two distinct conditions: chronic kidney disease (CKD) associated with Alport syndrome, and a specific type of pulmonary arterial hypertension linked to connective tissue diseases. Bardoxolone also has an offering for autosomal dominant polycystic kidney disease (ADPKD).